GLP-1 Peptide Atlas, by Delfa

Completed

Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients

The Physiology of Glucagon-like-peptide-1 Receptor Expression in Patients With Endogenous Hyperinsulinism - Correlation With Histopathology

Lead sponsor

University Hospital, Basel, Switzerland

Asset

Exenatide

GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Oncology

Key I/E criterion

—

Primary endpoint

•Detection of insulinomas, cure rate

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00937079

Org study IDOCS-01778-1

Timeline

Milestones

Study first posted2009-07-10estimated

Last update posted2015-01-09estimated

Study start2007-11 (month precision)

Primary completion2011-12actual (month precision)

Study completion2011-12actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Oncology

Eligibility

Who can enroll

Minimum age18 Years

Maximum age90 Years

SexAll

Healthy volunteersNot accepted

Sampling methodProbability sample

Study population text

residents of Switzerland

Inclusion criteria

•Biochemically proven endogenous hyperinsulinism confirmed by hypoglycaemia with neuroglycopenic symptoms, inadequately high serum insulin and C-peptide concentrations and negative sulfonylurea screening as well as low serum beta-hydroxybutyrate concentrations

•Able and willing to provide written informed consent

Exclusion criteria

•Renal insufficiency (creatinine > 140 micromol/l)

•Pregnancy or positive pregnancy test which will be performed in all patients without contraception and aged < 50 years

•Allergy to exendin-4 (Byetta®)

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other clinical outcomes

1 endpoint

Primary/protocol endpoint

Detection of insulinomas, cure rate

Time frame:one year

categorical status, improvement

Publications (3)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Clinical presentation of 54 patients with endogenous hyperinsulinaemic hypoglycaemia: a neurological chameleon (observational study).
Swiss medical weekly2018 Nov 5PMID30449018doi:10.4414/smw.2018.14682via pubmed nct search
Glucagon-like peptide-1 receptor imaging for localization of insulinomas.
The Journal of clinical endocrinology and metabolism2009 Nov (month)PMID19820010doi:10.1210/jc.2009-1082via CT.gov reference
Glucagon-like peptide 1-receptor scans to localize occult insulinomas.
The New England journal of medicine2008 Aug 14PMID18703486doi:10.1056/NEJMc0802045via CT.gov reference

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.